The Clinical Effect of Deferoxamine Mesylate on Edema after Intracerebral Hemorrhage

BACKGROUND AND PURPOSE: It has been shown that 3 days of 62 mg/kg/day deferoxamine infusion (maximum dose not to exceed 6000 mg/day) is safe and tolerated by intracerebral hemorrhage (ICH) patients. The aim of this study was to investigate the efficacy of deferoxamine mesylate for edema resolution a...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Yao, Zhao, Wei, Zhu, Chunpeng, Kong, Zhiping, Xu, Yan, Liu, Guangzhi, Gao, Xuguang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4395224/
https://www.ncbi.nlm.nih.gov/pubmed/25875777
http://dx.doi.org/10.1371/journal.pone.0122371

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4395224/
https://www.ncbi.nlm.nih.gov/pubmed/25875777
http://dx.doi.org/10.1371/journal.pone.0122371

Ejemplares similares